Suggested remit: To appraise the clinical and cost effectiveness of semaglutide within its marketing authorisation, in addition to a reduced calorie diet and increased physical activity, for managing overweight and obesity and the reduction of associated cardiovascular risk.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6441

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
27 February 2025 - 27 March 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6441
27 February 2025 In July 2024, NICE consulted on a scope for ID6441 semaglutide. Having reviewed the responses to consultation, we have reconsidered the approach we wish to take for this appraisal. A new consultation has been issued in Feb 2025 to propose to combine the appraisal of ID6441 with a review and update of existing guidance on the use of semaglutide for treating overweight and obesity (TA875). We also propose to update the terminated appraisal covering people aged 12 to 17 years (TA910).
12 December 2024 Referral
22 July 2024 - 19 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6441
22 July 2024 In progress. Scoping commenced.
16 May 2024 Topic selection
13 May 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual